Sanofi and MJFF to conduct trial on potential Parkinson’s disease treatment

Published: 19-Apr-2012
Research & Development

All data and results will be owned by MJFF and shared with Sanofi


Sanofi is to collaborate with the Michael J Fox Foundation (MJFF) by conducting a clinical trial to assess one of the French pharmaceutical firm’s potential treatments for Parkinson’s disease.

Under the terms of the agreement, MJFF will sponsor a Phase Ib clinical trial to assess the safety and tolerability of Sanofi’s AVE8112, a phosphodiesterase type IV inhibitor, in patients with Parkinson’s disease.

All data and results generated will be owned by MJFF and shared with Sanofi. Further development plans will be based upon the results of the study, which will be conducted in Baltimore and Los Angeles in the US.

Sanofi’s global r&d president Dr Elias Zerhouni said: ‘We hope to continue to develop relationships with private foundations like the Michael J Fox Foundation to pool our resources and maximise the potential of our drug portfolio to address unmet medical needs.’

Todd Sherer, chief executive of MJFF, said AVE8112 has shown ‘promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson’s disease’.

He added: ‘Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation’s approach and help the organisation speed scientific advances with potential to improve the treatment of Parkinson’s for patients today and in the future.’

  • Companies:
  • Sanofi
  • Michael J Fox Foundation
See more

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

Read more
The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  3. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  4. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)
Research & Development

Sanofi's tolebrutinib meets primary endpoints in Phase III HERCULES MS trial

The therapeutic has the ability to delay the onset of confirmed disability progression in patients, which is significant area of unmet need in the MS patient population
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Research & Development

Vesper Bio awarded grant to assess sortilin inhibitors to treat Parkinson’s disease

Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Subscribe now